Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis

Starting soon · Not applicable

Conditions studied: Amyloidosis

In brief

The goal of this clinical trial is to learn if a structured cardiac rehabilitation program can help people with cardiac amyloidosis improve their ability to exercise and their quality of life. The main questions it aims to answer are: Does cardiac rehabilitation raise peak oxygen uptake (VO₂ peak), which shows how well the heart and lungs work during exercise? Is cardiac rehabilitation safe and practical for people with cardiac amyloidosis? How does cardiac rehabilitation affect other exercise measures, heart function, symptoms linked to autonomic dysfunction, and quality of life? This study has no comparison group. Researchers will measure each participant's results before and after the rehabilitation program. Participants will: Complete a cardiac rehabilitation program for 5 weeks. Have tests before the program starts and again about 3 months later. These tests include: A cardiopulmonary exercise test A heart function test using electrical impedance A questionnaire about quality of life A blood sample A blood pressure test to check for orthostatic hypotension The study will include adults aged 18 or older with transthyretin cardiac amyloidosis who are able to perform an exercise test.

Key facts

Study ID

NCT07494942

Run by

University Hospital, Montpellier

People needed

40

Starts

2026-04-30

Expected to finish

2029-01-30

Last updated by the study team

2026-04-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 or older
• Cardiac ATTR amyloidosis diagnosed according to guidelines: Perugini grade II or III uptake on bone scintigraphy, without monoclonal gammopathy.
• Ability to undergo a stress test
• Available to complete the 5-week rehabilitation program within 30 days of the stress test

You may not qualify if…

• Uncontrolled ventricular arrhythmias
• NYHA Class IV heart failure
• Inability to give informed consent to participate in the study
• Inability to monitor the patient during the study period
• Subject not enrolled in a social security program or not eligible for such a program
• Pregnant or breastfeeding women, patients unable to give consent, protected adults, vulnerable persons
• Subjects deprived of liberty by judicial or administrative decision

Where it is running

• KRIEF — Montpellier, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.